ACC 2022: Late-breaking Science Video Collection
Published: 05 April 2022
-
Views:
7932
-
Likes:
7
-
Views:
7932
-
Likes:
7
-
23m 9sPart 1 | Session 1 ACC 22 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
28m 6sPart 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up Nicolas M Van Mieghem, Joost Daemen
-
16m 42sPart 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial Justin Ezekowitz, Harriette Van Spall
-
16m 57sPart 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial Harriette Van Spall, Dylan L Steen
-
15m 38sPart 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial Harriette Van Spall, Gregg C Fonarow, Tariq Ahmad
-
22m 47sPart 2 | Session 4 ACC 22 Late-breaker Discussion: The DIAMOND Trial Harriette Van Spall, Javed Butler, Faiez Zannad
-
9m 38sPart 3 | Session 1 ACC 22: Findings from the VALOR-HCM Trial Milind Y Desai
-
7m 19sPart 3 | Session 2 ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten Florian Rader
-
3m 19sPart 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial Manesh R Patel
-
3m 6sPart 3 | Session 4 ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease Frederik Zimmermann
-
3m 54sPart 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial Brian Bergmark
-
4m 22sPart 3 | Session 6 ACC 22: Results from the POISE-3 Trial Philip J Devereaux
-
6m 30sPart 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia Paolo Della Bella
-
6m 3sPart 3 | Session 8 ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab Lorenz Räber
-
3m 31sPart 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a) Steven E Nissen
-
4m 48sPart 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial Maura Marcucci
-
2m 55sPart 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials Michael J Reardon
-
7m 44sPart 3 | Session 12 ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR Duk-Woo Park
-
5m 41sPart 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study
-
2m 25sPart 3 | Session 14 ACC 22: Results from the GIPS-IV Trial Pim van der Harst, Marie-Sophie de Koning
-
9m 27sPart 3 | Session 15 ACC 22: FFR vs. IVUS-guided PCI in Intermediate Coronary Artery Stenosis: The FLAVOUR Trial Bon-Kwon Koo
-
5m 35sPart 3 | Session 16 ACC 22: Results From the EMPULSE Study – Empagliflozin Proves Beneficial for Patients With HF Mikhail Kosiborod
-
10m 24sPart 3 | Session 17 ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events Paul M Ridker
-
3m 50sPart 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study Felix Mahfoud
-
4mPart 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation Michelle Kittleson
-
12m 6sPart 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani Purvi Parwani
-
6m 15sPart 4 | Session 2 ACC 22: 5 Trials That Will Change Your Practice with Interventionalist, Dr Mirvat Alasnag Mirvat Alasnag
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Late-breaker Discussion Series
Part 3
Expert Interviews
Faculty Biographies
Erin D Michos
Associate Professor of Medicine and Director of Women's Cardiovascular Health
Dr Erin Michos is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She is the Director of Women’s Cardiovascular Heath and Associate Director of Preventive Cardiology with the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Dr Michos is an internationally known expert in Preventive Cardiology and Women’s Health and has authored over 350 publications. Her research has focused on cardiovascular disease among women; coronary artery calcium, inflammatory markers, and other novel biomarkers of cardiovascular risk; lipids; and vitamin D and other supplements. She is an Associate Editor for Circulation and the American Journal of Preventive Cardiology.
Following receipt of her medical degree from Northwestern University, Dr. Michos…